IntelGenx Provides Update on Research Collaboration Evaluating Montelukast VersaFilm® for the Treatment of Parkinson’s Disease

IntelGenx Corp. has recently announced a groundbreaking research collaboration with Karolinska University Hospital. The focus of this collaboration is to explore the potential of using Montelukast VersaFilm® as a treatment for Parkinson's Disease. Led by the esteemed Professor Per Svenningsson, an expert in clinical neuroscience, this study will delve into the efficacy of IntelGenx's innovative ..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 26.
  • textsms

Secarna Pharmaceuticals Demonstrates Therapeutic Activity of LNAplus™ ASO Targeting NLRP3 in Autoinflammatory Diseases

Secarna Pharmaceuticals, a biopharmaceutical company specializing in antisense oligonucleotide (ASO) therapies, has published new preclinical data in The Journal of Immunology. The data demonstrates the potent therapeutic activity of their LNAplus(TM) ASO targeting NLRP3 in debilitating autoinflammatory diseases. NLRP3 is a central component of the inflammasome pathway, which is overactive in ma..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 7.
  • textsms

Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson’s Disease

Vaxxinity has announced that its Phase 1 clinical trial of the investigational vaccine UB-312 for Parkinson's disease (PD) has met primary objectives. The vaccine was immunogenic in patients with early PD and generally safe and well-tolerated, demonstrating potential as a candidate for the prevention or modification of PD. UB-312 is an investigational synthetic peptide vaccine that targets toxic..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 23.
  • textsms